Not checkedNot checked for notices yet.
The future of malaria control in light of RTS,S
Priya Venkatesan
The Lancet Microbe · 2022
doi:10.1016/s2666-5247(22)00070-2 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The first antiparasitic RTS,S/AS01 (RTS,S) malaria vaccine, recommended by WHO in 2021 to be given to children living in regions with moderate-to-high transmission of Plasmodium falciparum malaria, is a huge step forward in the fight against malaria. However, many challenges remain for eliminating the disease. One such challenge is that the RTS,S vaccine is not expected to protect against the other human malaria parasites, namely Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and the zoonotic Plasmodium knowlesi.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.